Insider Selling: Aimmune Therapeutics Inc (AIMT) Insider Sells 1,648 Shares of Stock

Aimmune Therapeutics Inc (NASDAQ:AIMT) insider Douglas T. Sheehy sold 1,648 shares of Aimmune Therapeutics stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $35.87, for a total transaction of $59,113.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Aimmune Therapeutics Inc (NASDAQ AIMT) opened at $36.58 on Friday. Aimmune Therapeutics Inc has a 1 year low of $15.97 and a 1 year high of $40.65.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.09. analysts expect that Aimmune Therapeutics Inc will post -2.51 earnings per share for the current year.

AIMT has been the topic of several analyst reports. Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Saturday, October 21st. Credit Suisse Group set a $45.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 11th. Wedbush reissued an “outperform” rating and issued a $70.00 target price on shares of Aimmune Therapeutics in a research report on Friday, December 1st. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 8th. Finally, BidaskClub downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $57.25.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Aimmune Therapeutics by 12.6% during the second quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock valued at $50,923,000 after purchasing an additional 276,978 shares in the last quarter. Point72 Asset Management L.P. grew its position in Aimmune Therapeutics by 10.2% during the third quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock valued at $27,222,000 after purchasing an additional 101,855 shares in the last quarter. State Street Corp grew its position in Aimmune Therapeutics by 26.6% during the second quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock valued at $22,351,000 after purchasing an additional 228,429 shares in the last quarter. Citadel Advisors LLC lifted its stake in Aimmune Therapeutics by 3,092.5% in the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after acquiring an additional 542,111 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Aimmune Therapeutics by 24.7% in the second quarter. Northern Trust Corp now owns 391,990 shares of the biotechnology company’s stock valued at $8,059,000 after acquiring an additional 77,744 shares during the last quarter. 73.54% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2018/02/09/insider-selling-aimmune-therapeutics-inc-aimt-insider-sells-1648-shares-of-stock.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply